ReviewJournal of medicine and life2026
Autoimmune thyroiditis in pregnancy: epidemiology, clinical impact, and contemporary management challenges.
Review in Journal of medicine and life, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune thyroiditis represents the most common cause of thyroid dysfunction in women of reproductive age and is frequently encountered during pregnancy. The presence of thyroid autoantibodies, particularly anti-thyroid peroxidase antibodies, has been associated with adverse obstetric outcomes even in the absence of overt thyroid dysfunction. However, optimal screening, monitoring, and treatment strategies remain areas of ongoing debate. This study aimed to review recent evidence on the epidemiology, clinical impact, diagnosis, management, and emerging research directions of autoimmune thyroiditis in pregnancy. A narrative review of observational studies, randomized controlled trials, meta-analyses, and international clinical guidelines published predominantly within the last five years was conducted, focusing on maternal and fetal outcomes, diagnostic approaches, and therapeutic strategies. Autoimmune thyroiditis affects a substantial proportion of pregnant women worldwide and is associated with increased risks of miscarriage, preterm delivery, hypertensive disorders of pregnancy, and postpartum thyroiditis. These associations are observed not only in women with overt or subclinical hypothyroidism but also in euthyroid women with thyroid autoimmunity. While levothyroxine therapy is clearly indicated in overt and selected cases of subclinical hypothyroidism, evidence does not support routine treatment in euthyroid antibody-positive women. Current guidelines recommend targeted screening and close biochemical monitoring rather than universal intervention. Autoimmune thyroiditis in pregnancy is a clinically relevant condition with important implications for maternal and fetal health. A risk-stratified, individualized approach to diagnosis and management is essential, balancing the benefits of treatment against the risks of overtreatment. Further high-quality research is needed to refine risk prediction and identify subgroups that may benefit from targeted therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.